Phaseline

Targets › RARG

RARG (Retinoic acid receptor gamma): drug programs, companies and trials

10 programs from 10 companies in 29 trials: 17 Phase 2, 5 Phase 3, 4 Phase 4, 3 Phase 1; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. (UniProt, P13631)

Open in Phaseline: the race on RARG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IR INNOVATE RESEARCH PRIVATEAdapalene
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 4Acne; Viral WartsFeb 2027
Galderma R&DTrifarotene
Retinoic acid receptor gamma agonist
RARGPhase 3Acne VulgarisDec 2026
Centre Hospitalier Universitaire de NiceIsotretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 3Acne VulgarisSep 2027
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityATRA (All-trans retinoic acid)
Retinoic acid receptor agonist
RARA, RARB, RARGPhase 2Oral Cavity CancerDec 2026
St. Petersburg State Pavlov Medical UniversityVitamin A
Retinoid receptor agonist; supports immune tolerance and graft-versus-host disease prevent
RARA, RARB, RARGPhase 2Acute Lymphoblastic LeukemiaMay 2027
Children's Oncology GroupIsotretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 2Ganglioneuroblastoma, NodularSep 2027
HighField BiopharmaceuticalsTretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 2Glioma; Acne Vulgaris; Melasma (Facial Melasma); APL …Dec 2028
Fudan UniversityAll Trans Retinoic Acid (ATRA)
Retinoic acid receptor agonist
RARA, RARB, RARGPhase 2Triple Negative Breast Cancer (TNBC)Sep 2029
Zagazig UniversityIsotretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 1OnychomycosisDec 2026
National Cancer Institute (NCI)Isotretinoin
Retinoic acid receptor agonist
RARG, RARB, RARAPhase 1Recurrent NeuroblastomaMar 2027

Conditions

Acne Vulgaris (3) Glioma (2) Persistent Isolated Chemotherapy-Induced Thrombocytopenia (2) Recurrent Neuroblastoma (1) Onychomycosis (1) Acne (1) Viral Warts (1) Melasma (Facial Melasma) (1) APL (1) Oropharynx Cancer (1) Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA (1) Multiple Myeloma in Relapse (1)

Modalities

small molecule (6), mixed (2), antibody (2)

Companies

National Cancer Institute (NCI) (1) Zagazig University (1) Centre Hospitalier Universitaire de Nice (1) IR INNOVATE RESEARCH PRIVATE (1) HighField Biopharmaceuticals (1) Children's Oncology Group (1) Fudan University (1) Galderma R&D (1) St. Petersburg State Pavlov Medical University (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)

Related targets

RARB (9) RARA (9)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.